Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 5/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1495528 | 0.85 | GRM2 (0.45) | XDHGRM2 | |
| SCHEMBL2171775 | 0.81 | P2RX3 (0.43) | XDH | |
| SCHEMBL2171780 | 0.81 | CYP11B2 (0.38) | XDHSLC22A12CYP11B2GRM2ABL1 | |
| SCHEMBL3474932 | 0.81 | XDH (0.40) | XDHGRM2 | |
| SCHEMBL1495652 | 0.77 | XDH (0.42) | XDHGRM2 | |
| SCHEMBL1495671 | 0.77 | TDP1 (0.41) | XDHGRM2 | |
| SCHEMBL16195384 | 0.76 | DHODH (0.52) | XDH | |
| SCHEMBL16418294 | 0.76 | GRM2 (0.39) | XDHCYP11B2GRM2 | |
| SCHEMBL16195427 | 0.75 | GRM2 (0.39) | XDHGRM2 | |
| SCHEMBL2383724 | 0.75 | GRM2 (0.44) | XDHGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133122-B2 | Amide compounds, compositions and uses thereof | EVOTEC AG (DE) | 2015-09-15 | — | — | US | disclosed |
| US-9133122-B2 | Amide compounds, compositions and uses thereof | EVOTEC AG (DE) | 2015-09-15 | — | — | US | disclosed |
| US-9133122-B2 | Amide compounds, compositions and uses thereof | EVOTEC AG (DE) | 2015-09-15 | — | — | US | disclosed |
| US-20140323532-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2014-10-30 | — | — | US | disclosed |
| US-20140323532-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2014-10-30 | — | — | US | disclosed |
| US-20140323532-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2014-10-30 | — | — | US | disclosed |
| US-20110237578-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-09-29 | — | — | US | disclosed |
| US-20110237578-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-09-29 | — | — | US | disclosed |
| US-20110237578-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | EVOTEC AG (DE) | 2011-09-29 | — | — | US | disclosed |
| EP-2346825-A2 | MODULATORS OF P2X3 RECEPTOR ACTIVITY | Evotec AG (DE) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010033168-A2 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | RENOVIS, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237578-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | ADORA2B, IL1B, AVPR1B | XDH 375/4885SLC22A12 3294/4885CYP11B2 436/4885 |
| US-20140323532-A1 | AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | IL1B, ADORA2B, AVPR1B | XDH 515/4885SLC22A12 3620/4885CYP11B2 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.